KPV Capsules: There's No Verified Standalone Yet, and the One Gut Blend That Clears Our Bar

Here is the verdict most "best KPV capsules" lists won't give you: as of June 2026, there is no standalone, pure-KPV capsule from a transparency-vetted vendor that clears our certificate-of-analysis bar. The pure-KPV products that exist come from sellers we can't independently stand behind, and the KPV products we can grade are multi-ingredient gut blends. Exactly one of those blends clears the bar.

That is the honest map, and it's the opposite of what a normal affiliate roundup tells you. We grade vendor transparency, not products. We describe, we don't prescribe. Nothing here is medical advice.

This matters because KPV is genuinely interesting. Unlike most peptides, it has a real mechanical reason to work orally for the gut, which is exactly why buyers go looking for a capsule. So this guide does two jobs at once. It gives you the honest science on why oral KPV is defensible for the gut and nowhere else, and it tells you precisely what is buyable today, what we recommend, and what we deliberately left off the list and why. See our peptide reference for the wider catalog.

Start Here: Which KPV Buyer Are You?

KPV shoppers split into two camps, and the right answer is different for each.

• You want pure KPV, dosed precisely. Your priority is a single-ingredient capsule you can verify with one identity check and titrate on your own. The honest news: no standalone KPV from a vendor we've transparency-vetted is available right now. Standalone products exist (we name them below), but we won't point a monetized buy-link at a seller we can't stand behind, and we won't fabricate one. Your move is to verify a COA yourself using the checklist further down, or wait.
• You want the gut-inflammation benefit. Your priority is the outcome KPV is actually studied for, gut-local anti-inflammatory action, and you're open to a blend that pairs KPV with complementary peptides. This is where the one product that clears our bar lives: a COA-gradeable gut formula that contains KPV. Skip to what you can actually buy.

Either way, read the science first. It's the difference between buying KPV for what it does and buying it for what a product page wishes it did.

What Is KPV? The Tripeptide Behind the Hype

KPV is a three-amino-acid peptide, Lys-Pro-Val, and that small size is the whole story. It is the C-terminal fragment of alpha-melanocyte stimulating hormone (alpha-MSH), occupying positions 11 through 13 of that larger hormone. Chemical formula C16H30N4O4, molecular weight 342.43 g/mol as the free base, CAS number 67727-97-3.

Memorize that one number. 342.43 Da is the identity check that lets you spot a fake later, because mass spectrometry on a real KPV product has to land there (or near 389 Da for the acetate salt, more on that below).

A quick salt-form note that matters twice over. Some vendors sell KPV as the acetate salt (Ac-KPV-NH2, roughly 389 Da), others as the free base. The acetate adduct adds around 46 Da, which means a labeled 500 mcg acetate dose delivers about 443 mcg of active free-base peptide. That gap shows up in your dosing math and on the COA, so it is worth flagging early.

KPV inherits two properties from its parent hormone. It is anti-inflammatory, suppressing the NF-kappaB pathway that drives pro-inflammatory cytokines. It is also antimicrobial against certain bacteria and fungi. Those are what the molecule is built to do at a mechanistic level, not a list of conditions it treats.

The payoff of the chemistry is simple. At three amino acids and 342 Da, KPV sits near the textbook size for the gut's di- and tripeptide transporter. For contrast, BPC-157 runs about 1,419 Da, far too large for that carrier. KPV's size is exactly why the oral question has a real answer instead of a marketing one, and that transporter is the next section.

Why KPV Capsules Actually Work Orally When Most Peptides Don't

If stomach acid destroys peptides, a KPV capsule should be useless. For the gut, it isn't, and the reason is a transporter most people have never heard of.

KPV is absorbed by PepT1 (gene name SLC15A1), the proton-coupled oligopeptide transporter that sits in the lining of your intestine. This is active transport, not the passive diffusion that larger peptides fail at. PepT1's normal day job is pulling di- and tripeptides out of digested dietary protein, and a three-amino-acid molecule is precisely what it grabs.

KPV is unusually good at this. In a 2008 Gastroenterology study from a team at Emory University, the Km for KPV in PepT1-expressing intestinal cells came in around 160 micromolar, among the lowest values ever reported for any human PepT1 substrate. Low Km means tight binding, and tight binding means efficient uptake even when the dose is small. For comparison, the standard reference substrate glycine-sarcosine binds far more weakly, with a Km at or above 1 millimolar.

Then comes the part that makes oral KPV genuinely interesting. PepT1 is nearly absent in healthy colon tissue but gets significantly upregulated in inflamed colonic epithelium during inflammatory bowel disease. So the more inflamed the tissue, the more transporter it expresses, and the more KPV it pulls in. The disease state recruits its own delivery system.

That reframes the whole bioavailability argument. For gut-local action, systemic bioavailability is not the relevant metric. KPV doesn't need to survive into your bloodstream to act in the colon, because the colonic cells take it up directly through PepT1 at the surface where the inflammation lives.

Keep the claim honest and narrow, though. Quantitative human oral bioavailability for KPV is not well established, and for systemic or skin targets the oral route is essentially uncharacterized (that is what topical and subcutaneous routes are for). The defensible statement is specific: oral KPV has a real rationale for the gut, and only the gut.

This is also why KPV sits in the "works (gut)" tier of our oral peptides guide, alongside the handful of peptides with a real absorption rationale, and not in the waste tier where large molecules dissolve into nothing useful.

What the Research Actually Shows (and What It Doesn't)

You have probably been whipsawed between "KPV heals IBS and eczema" hype and "it's all unproven" dismissal. The calibrated truth sits between them, and it comes with receipts. Every study below is preclinical. Read it as mechanism, not as a cure.

The anchor is that 2008 Dalmasso paper in Gastroenterology. In cell culture, KPV at just 10 nanomolar inhibited IL-1beta-induced NF-kappaB activity and dampened MAPK signaling, which is potent for a tripeptide. In a DSS-induced colitis mouse model, oral KPV in drinking water cut myeloperoxidase activity (a marker of neutrophil infiltration) by roughly half and lowered IL-6 and IL-12 messenger RNA in colon tissue. In a second, mechanistically different TNBS colitis model, MPO dropped about 30% with reductions in IL-1beta, IL-6, TNF-alpha, and IFN-gamma. Two different models, same direction, via the oral route.

The antimicrobial side comes from a 2000 paper in the Journal of Leukocyte Biology (Cutuli and colleagues). KPV showed activity against Staphylococcus aureus and Candida albicans, and the mechanism is the interesting part: it enhanced neutrophil killing of those pathogens rather than suppressing immune function. That is the "modulates without suppressing" distinction from steroids, framed mechanistically and not as a treatment.

A 2006 rabbit corneal study (Bonfiglio) supports the skin and wound-healing angle. Topical KPV drove 100% corneal re-epithelialization within 60 hours versus 0% in untreated controls, with nitric oxide identified as a mediator. Note the route: that result is topical, not oral, and it speaks to skin targets rather than gut.

The 2017 Xiao study in Molecular Therapy is impressive and easy to misread. Using hyaluronic-acid-functionalized nanoparticles to target the inflamed colon, researchers normalized colitis markers in mice at just 16 mcg/kg per day, roughly a thousandfold less than bulk dosing. That is a targeted-delivery proof of concept. Commercial KPV capsules do not use that nanoparticle system; they are simple encapsulation, so do not assume capsule efficacy equals nanoparticle efficacy.

Now the honest beat. As of June 2026 there are zero registered or completed human Phase I, II, or III trials for KPV in any indication. The FDA assigned it Evidence Level D/C in its 2026 review and noted human data is sparse. Anyone citing human efficacy results is overclaiming. We describe the mechanism and what the community uses it for, and we do not say KPV treats IBD, IBS, eczema, or psoriasis.

KPV Dosage: What the Research Protocols Look Like

Before any numbers: these are conventions extrapolated from animal data and community protocols, not medical advice and not human dose-finding. No human trial has ever established a KPV dose, so treat the figures below as the market's working assumptions rather than validated guidance.

The commonly cited oral range is 200 to 500 mcg per day. A conservative approach starts at 200 to 250 mcg daily for the first week to gauge tolerance, then moves to the standard 500 mcg per day, sometimes split into two 250 mcg doses. Aggressive gut protocols cite 1,000 to 1,500 mcg per day, but there is no validating data behind the upper end. That wide spread, from 200 to 1,500 mcg, is itself a symptom of the missing human evidence.

The one genuinely actionable timing rule ties straight back to the transporter. Take KPV on an empty stomach, about 30 minutes before food. Dietary di- and tripeptides compete for the same PepT1 transporter, so dosing when PepT1 is free gives KPV a clearer run at uptake.

On cycling, the community consensus is 4 to 8 week cycles with 2 to 4 week breaks, and a 5-days-on, 2-days-off weekly pattern shows up often. None of that is validated specifically for KPV; it is borrowed convention.

Match the route to the target. Oral suits gut and GI goals, which is the mechanistically rational case covered above. Topical suits skin, backed by the corneal wound-healing evidence. Subcutaneous injection is used for systemic anti-inflammatory aims, precisely because oral systemic bioavailability is uncharacterized. And one more callback to the chemistry: a 500 mcg dose of the acetate salt delivers roughly 443 mcg of active free-base KPV, so check which form your product's COA states before you trust the dose on the label.

What You Can Actually Buy: The COA-Graded KPV Landscape

Here is the part the listicles fudge. The KPV market today has two shelves, and only one product across both clears our bar.

Shelf 1: standalone pure KPV. These exist (Swiss Chems sells a 250 mcg capsule, Amino Innovations a 500 mcg capsule, and several gray-market research outfits sell powder or "research" capsules). Standalone is genuinely the better technical choice for precise dosing and the simplest verification, just one identity check at 342.43 Da. The catch is the one that drives this whole page: we do not have a transparency-vetted, COA-graded relationship with any standalone KPV seller. So we name them for your own research, and we do not point a monetized buy-link at them, and we will never fabricate affiliate parameters to do so.

Shelf 2: gut blends that contain KPV. These pair KPV with complementary gut peptides. Most don't survive our COA scrutiny (see the next section). One does: Limitless Life's Gastro-Inflammation Research Formula.

Why a blend can be a reasonable pick at all: KPV's strongest real-world application is gut-local synergy. The mechanisms in a gut formula are genuinely complementary, hitting different pathways at once, KPV on the NF-kappaB and PepT1 inflammation layer, BPC-157 on mucosal repair, N-acetyl-larazotide on tight junctions. No study has compared the combination against any single peptide, so the synergy is mechanistic logic, not measured outcome. But for the gut use case, a well-documented blend is a defensible buy. The non-negotiable: a blend's COA has to verify every component at its stated concentration, not just print one combined number.

Some links here are affiliate links, and affiliate status never changes a grade. Grades reflect COA evidence only. See our affiliate disclosure for the full policy, our COA verification methodology for how we read these documents, and the vendor directory for who publishes them.

Why These KPV Products Didn't Make the List

The disqualifications are the honest part of any recommendation, so here they are with reasons.

• BioLongevity BioGutPro (BPC-157 + KPV + GHK-Cu + larazotide). This blend contains KPV and is otherwise a plausible gut formula, but we left it off on a specific, verifiable ground. Its BPC-157 component comes from BioLongevity, and independent third-party testing coverage rates BioLongevity's BPC-157 poorly enough that the honest instruction is not to source BPC-157 from that vendor. We're not going to route you to a multi-peptide blend whose BPC-157 half we'd tell you to avoid on its own. This is a vendor-component judgment, not a verdict on BPC-157 or KPV as molecules. It's also why this KPV page is stricter than our broader gut-stack coverage: when a page's whole job is finding you a clean KPV product, a weak component anywhere in the blend is disqualifying.
• Standalone gray-market KPV with no openable COA. A "lab tested" claim with no batch-specific document you can read isn't evidence. For a product you swallow, identity (mass spec to 342.43 Da) and HPLC purity have to be on a certificate that matches your lot. No document, no grade.
• BioPerine / piperine-enhanced KPV. Some products add piperine and advertise it as an absorption booster. Piperine enhances passive absorption by inhibiting P-glycoprotein efflux and slowing gut motility, which KPV's PepT1 active transport does not rely on. A BioPerine-branded KPV product is being marketed as a generic supplement, not as the PepT1 substrate it actually is, which is a tell about how well the seller understands what they're selling.

What Would Change Our Mind

This verdict is a snapshot, not a permanent stance. Any of the following would move a product onto the recommended list:

• A standalone pure KPV capsule from a transparency-vetted vendor, carrying a batch-specific COA with mass-spec identity at 342.43 Da and HPLC purity at 98% or higher from a named independent lab. This is the product the market is missing, and the first vendor to ship it credibly would likely top this page.
• A gut blend with full per-component COA disclosure, confirming the KPV content at its stated concentration rather than a single combined purity figure, from a vendor whose every component we'd recommend on its own.
• Actual human data. Any registered human trial or pharmacokinetic study would change how we frame efficacy and dosing, both of which are currently extrapolated from animals.

How to Verify a KPV Product on Its COA

Whichever shelf you buy from, a real product proves itself on its certificate of analysis. KPV's COA checklist is short and specific:

1. Identity. Mass spectrometry has to match KPV's free-base mass of 342.43 Da, or roughly 389 Da for the acetate salt, within about a dalton. Wrong mass means it isn't KPV. This is the primary check.
2. Purity. HPLC purity of 98% or higher by area, ideally with a chromatogram showing one dominant peak. Below 95% is substandard.
3. A named independent lab. Not "tested in-house." A specific third-party analytical lab, ideally ISO 17025 accredited.
4. A batch-specific COA that matches the lot on your bottle and is dated within roughly the last 12 to 18 months.
5. For blends, per-component verification. Each ingredient confirmed at its stated concentration, not a single combined number. This is the non-negotiable bar for any blend.

Why this matters: independent lab testing has repeatedly found research peptides below their label purity, and some samples that aren't the labeled molecule at all. We won't put a fake-precise percentage on that, because the widely-circulated figures trace to gray-market aggregators. The directional point stands.

Is KPV Legal? Safety and Regulatory Status in 2026

The short answer most people get wrong: KPV is not prohibited, but it is also not authorized. Removal from a prohibition list is not the same as a green light.

KPV came off the FDA's Category 2 bulk drug substance list on April 15, 2026, one of 12 peptides taken off. Category 2 was the list of substances the FDA had determined should not be used in compounding, so removal lifts an explicit prohibition. It does not place KPV on the authorized 503A bulks list. That requires a separate review by the Pharmacy Compounding Advisory Committee, scheduled for July 23 to 24, 2026, plus a follow-on FDA determination. The earliest authorized compounding access would be late in the third quarter of 2026, and only if PCAC recommends adding it. Until then KPV is neither prohibited nor authorized.

KPV is not DEA-scheduled, and possession for private research use is not illegal in the US as of June 2026. The safest and most accurate framing is research-use-only, purchased from a research vendor.

On safety, the ceiling of evidence is "well tolerated in mouse colitis models." No human safety or toxicity studies exist. Two precautionary contraindications are worth stating plainly, both based on caution rather than documented harm: pregnancy and breastfeeding (no data at all), and a personal history of cancer or melanoma (theoretical, because alpha-MSH and MC1R signaling are involved in melanocyte and melanoma biology). For competitive athletes, KPV is likely prohibited under WADA's S0 category, which covers non-approved pharmacological substances, even though it is not named explicitly on the list.

This is the whole reason we frame KPV as research-use-only and grade transparency instead of products. The regulatory and safety picture is unsettled, and pretending otherwise would be the opposite of honest.

The Bottom Line on KPV Capsules

KPV is a real exception in a category full of theater. The oral capsule form is mechanistically defensible for the gut specifically, through PepT1 transport and the inflamed colon's self-targeting upregulation, and not for systemic or skin goals where the oral route is uncharacterized. But every efficacy claim is preclinical, from cell cultures and two mouse colitis models. There are no human trials, the FDA files it at Evidence Level D/C, and 2026 is a regulatory gray zone where Category 2 removal is not authorization.

So the honest buying verdict, today:

• If you want pure KPV, the right form exists but no vendor we've transparency-vetted sells it. Verify a standalone product's COA yourself against the five-point checklist above, or wait for one we can stand behind.
• If you want the gut benefit, the one KPV-containing product that clears our COA bar is the Limitless gut formula above. It's a blend, which is fine, because gut-local synergy is exactly KPV's best use case.
• Either way, verify identity and purity first, 342.43 Da by mass spec, 98%-plus HPLC, a named independent lab, per-component testing for any blend. Only then does a purchase make sense.

We grade transparency, not products, and affiliate status never moves a grade. The vendor directory is where that verification work lives.

FAQ

Is there a pure KPV capsule I can actually trust?

Not from a vendor we've transparency-vetted, as of June 2026. Standalone pure KPV capsules do exist (Swiss Chems at 250 mcg, Amino Innovations at 500 mcg, plus gray-market research sellers), and standalone is technically the better form for precise dosing and simple verification. But we don't have a COA-graded relationship with any of them, so we name them for your own research without a buy-link. If you go that route, verify the COA yourself: mass spec at 342.43 Da, HPLC purity 98%-plus, named independent lab, batch-matched to your bottle.

Won't stomach acid just destroy KPV before it reaches the gut?

For gut targets, no, and that is the point. KPV is taken up by PepT1, the active di- and tripeptide transporter in your intestinal lining, with a Km around 160 micromolar (very tight binding). The target is local colon tissue, not your bloodstream, so KPV doesn't need to survive into circulation. Inflamed colon also upregulates PepT1, pulling in proportionally more KPV.

Is KPV a drug, supplement, or research chemical?

None cleanly. KPV is not an FDA-approved drug and not a grandfathered DSHEA dietary supplement ingredient. After its April 2026 removal from the FDA's Category 2 list, it sits in a regulatory gray zone, pending the July 2026 PCAC review for any authorized compounding status. The honest and safest label is research-use-only, sold through a research peptide vendor rather than as a consumer supplement.

Is there human trial data showing KPV works for IBD or gut health?

No. As of June 2026 there are zero completed human Phase I, II, or III trials for KPV in any indication. All the evidence is preclinical: cell-culture work and mouse colitis models, principally Dalmasso 2008 and Xiao 2017. The FDA assigned KPV Evidence Level D/C and noted human data is sparse. Anyone presenting human efficacy results for KPV is overclaiming.

Should I buy standalone KPV or a blend with BPC-157?

It depends on which is verifiable. Standalone KPV is easier to verify (one identity check at 342.43 Da) and lets you dose precisely, but right now no standalone comes from a vendor we've vetted. A blend offers complementary mechanisms in one capsule, but its COA must verify each component at its stated concentration and you can't adjust doses independently. For the gut-repair use case, a well-documented blend from a vendor whose every component you'd trust is reasonable, which is why our one pick is a blend.

What should I check on a KPV COA?

Five things. Mass spectrometry confirming 342.43 Da for the free base or roughly 389 Da for the acetate salt. HPLC purity of 98% or higher. A named, independent third-party lab, not in-house testing. A batch-specific COA matching your bottle's lot. And for blends, per-component verification at stated concentrations. Our COA verification guide covers each field.

Is KPV legal to buy in the US?

As of June 2026, KPV is not DEA-scheduled and possession for private research use is not illegal. It was removed from the FDA's Category 2 prohibition list in April 2026 but is not yet on the authorized 503A compounding bulks list. That decision waits on the PCAC vote scheduled for July 23 to 24, 2026. The safest framing remains research-use-only.